Imagine a life where you're constantly fighting to stay awake, struggling to focus, and your memory feels like a sieve. For adults with Narcolepsy Type 1 (NT1), this is a daily reality. But what if there was a way to reclaim your cognitive abilities?
Recent findings suggest that a new treatment, oveporexton, might just be the answer. A secondary analysis of a phase 2 clinical trial (NCT05687903) has revealed promising results: oveporexton, an oral orexin receptor 2 agonist, showed significant improvements in attention, memory, and executive function in adults with NT1. This is a big deal because it targets the core cognitive challenges faced by individuals with this condition.
So, what exactly did the study entail? Researchers examined the effects of oveporexton on cognitive function over 8 weeks of daily dosing. They used a series of tests to measure different aspects of cognition. These included the Psychomotor Vigilance Task (PVT) for attention, the Continuous Paired Associate Learning (CPAL) test for memory, and the One Back (ONB) test and International Digit Symbol Substitution Test–symbols (IDSST-s) for executive function. The goal was to see if oveporexton could help patients think more clearly and perform better on these cognitive tasks.
Led by Dr. Gert Jan Lammers, the study involved 112 participants. They were divided into different groups and given varying doses of oveporexton or a placebo. The doses were administered twice daily, 3 hours apart. The dose groups were 0.5/0.5 mg, 2/2 mg, 2/5 mg, 7 mg/placebo, or placebo/placebo.
The results were encouraging. Oveporexton showed improvements across the board. For example, in the PVT, the placebo-adjusted changes from baseline in lapses were significant across all active dose groups. Similarly, CPAL errors also decreased significantly with oveporexton. These improvements extended to working memory, processing speed, and executive function as well. The improvements in IDSST-s correct responses were particularly noteworthy, with the highest dose group showing the most significant gains.
But here's where it gets controversial... The initial phase 2 trial also highlighted the potential of oveporexton to reduce microsleeps and improve wakefulness. The study showed that patients on oveporexton experienced significant reductions in microsleep rates and delayed the first occurrence of microsleep. This is crucial because it addresses the excessive daytime sleepiness that is a hallmark of NT1. The microsleep rates decreased from 6 microsleeps per 10 minutes at baseline to fewer than 2 per 10 minutes after 4 and 8 weeks of treatment.
And this is the part most people miss... While the study showed significant improvements in several cognitive areas, it is important to note that the average microsleep duration did not change significantly in any of the treatment arms. This suggests that while oveporexton can reduce the frequency of microsleeps, it may not affect their duration. The placebo group showed minimal changes in microsleep frequency and timing, which reinforces the active effect of oveporexton.
What do you think? Does this research give you hope for the future of NT1 treatment? Do you think the benefits of improved cognitive function outweigh the potential side effects? Share your thoughts in the comments below!
